Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Chang

Showing results (371-380 of 386) with videos related to

Pageof 39
Sort By:
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
Brain Pathology (Zurich, Switzerland)|November 3, 2020
Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasmsEmily A Sloan, Jason Chiang, Javier E Villanueva-Meyer, et al.
Science (New York, N.Y.)|December 17, 2013
Mutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaBrett E Johnson, Tali Mazor, Chibo Hong, et al.
Neuro-Oncology|May 3, 2025
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad Scope and Implementation - A Progress ReportMartin J van den Bent, Michael A Vogelbaum, Tim Cloughesy, et al.
The Lancet. Oncology|July 31, 2025
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomasNorbert Galldiks, Philipp Lohmann, Mariam Aboian, et al.
Nature Genetics|August 28, 2012
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutationRobert B Jenkins, Yuanyuan Xiao, Hugues Sicotte, et al.
The New England Journal of Medicine|June 11, 2015
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in TumorsJeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Pageof 39

Showing results (371-380 of 386) with videos related to

Sort By:
Pageof 39
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
Brain Pathology (Zurich, Switzerland)|November 3, 2020
Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasmsEmily A Sloan, Jason Chiang, Javier E Villanueva-Meyer, et al.
Science (New York, N.Y.)|December 17, 2013
Mutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaBrett E Johnson, Tali Mazor, Chibo Hong, et al.
Neuro-Oncology|May 3, 2025
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad Scope and Implementation - A Progress ReportMartin J van den Bent, Michael A Vogelbaum, Tim Cloughesy, et al.
The Lancet. Oncology|July 31, 2025
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomasNorbert Galldiks, Philipp Lohmann, Mariam Aboian, et al.
Nature Genetics|August 28, 2012
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutationRobert B Jenkins, Yuanyuan Xiao, Hugues Sicotte, et al.
The New England Journal of Medicine|June 11, 2015
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in TumorsJeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Pageof 39